RecruitingNot ApplicableNCT06006637
Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder
Sponsor
State University of New York - Upstate Medical University
Enrollment
80 participants
Start Date
Oct 17, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will consist of a randomized, double-blind, sham-controlled clinical trial at SUNY Upstate Medical University and Mt. Sinai Medical Center with 80 autistic children evaluating the effects of transcranial photobiomodulation (tPBM) on multiple clinically validated scales.
Eligibility
Min Age: 2 YearsMax Age: 8 Years
Inclusion Criteria3
- Ages 2 - 8
- Autism spectrum disorder diagnosis
- CARS-2 score of 30 - 45
Exclusion Criteria7
- CARS scores less than 30 or over 45.
- Taking psychotropic medications.
- Having skin lesions on scalp
- Having history of seizures
- Having history of abnormal EEG
- Being a relative of the PI or a researcher
- Having implanted devices (including cochlear implants).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICECognilum TM: Light Treatment Condition
The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06006637
Related Trials
Promoting Emotional and Autonomic Control Through Guided Breathing Exercises for Emerging Adults With Autism
NCT072381532 locations
International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
NCT0559071521 locations
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
NCT043227342 locations
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
NCT065233871 location
DINO RCT - Treating Anxiety in Children With Autism
NCT060669831 location